论文部分内容阅读
目的:评价沙美特罗/氟替卡松复合干粉吸入剂(SFC)与布地奈德干粉吸入剂(BUD)治疗哮喘的成本-效果。方法:在SFC50/100μg、bid与BUD400μg、bid治疗386例哮喘患者的多中心、随机临床对照试验基础上回顾性收集资料,进行成本-效果分析,效果指标采用成功治疗周、无症状日和未受累日;成本指标采用直接医疗服务成本。结果:SFC组的平均每日治疗成本(15.6元)略高于BUD组(13.8元),但SFC组每成功治疗周、无症状日和未受累日成本分别为166.5元、33.4元和41.2元,均低于BUD组(188.6元、50.6元和66.1元);SFC组相对于BUD组的增量成本-效果比分别为每成功治疗周88.7元、每无症状日9.4元和每未受累日10.8元。结论:SFC50/100μg、bid治疗哮喘的成本-效果优于BUD400μg、bid。
OBJECTIVE: To evaluate the cost-effectiveness of salmeterol / fluticasone complex dry powder inhalers (SFC) and budesonide dry powder inhalers (BUD) in the treatment of asthma. Methods: We retrospectively collected data on the basis of multicenter, randomized, controlled clinical trial of SFC50 / 100μg, bid and BUD400μg, bid in 386 asthmatic patients for cost-effectiveness analysis. The efficacy indicators were successfully treated for weeks, asymptomatic days and not The day of involvement; the cost indicator adopts the direct medical service cost. Results: The mean daily treatment cost of SFC group (15.6 yuan) was slightly higher than that of BUD group (13.8 yuan), but the cost of asymptomatic day and non-affected day in SFC group was 166.5 yuan, 33.4 yuan and 41.2 yuan respectively , Lower than that of BUD group (188.6 yuan, 50.6 yuan and 66.1 yuan respectively). The incremental cost-effectiveness ratio of SFC group to BUD group was 88.7 yuan per successful treatment week, 9.4 yuan per asymptomatic day, and every non-affected day 10.8 yuan. CONCLUSIONS: The cost-effectiveness of SFC50 / 100μg bid for the treatment of asthma is superior to that of BUD400μg bid.